Feeds:
Posts
Comments

Archive for the ‘Hep C’ Category

 

MARCH 19, 2014
 
SPECIAL SPEAKER: DR. PATRICK KENNEY
 
Topic for Wed Group is “New Treatment For
Hepatitis C”
 
Refreshments Provided by Midland Medical
and Pride RX Pharmacy
 
 Fortunately, in the past three months, there have been great advances in the treatment of Hepatitis C for both people who have the virus and those who also infected with HIV.  It is my pleasure to present the options that are available now and to answer any questions.
 
 

Viral hepatitis has been affected the LGTB community since before the HIV epidemic. The medical community has made great strides in eradicating hepatitis A and B with the advent of vaccinations and anti-viral medications.  Hepatitis C, however, has been an immense challenge for health care providers and their patients due to its tenacity to treatment to a very limited set of options.    I look forward to meeting with you all!

 

  
Photo
 
photo of Dr. Patrick Kenney
 
DR PATRICK KENNEY
Specialist in Infectious Disease: General Infectious Disease, HIV/AIDS Medicine, International Health, Travel & Tropical, STD Medicine, Transplant/Immunocompromised States, Healthcare Associated Infections

954-565-0875  1421 E. Oakland Park Blvd, Suite #101
Oakland Park, FL

 
 

Read Full Post »

MARCH 19, 2014
SPECIAL SPEAKER: DR. PATRICK KENNEY
Topic for Wed Group is “New Treatment For
Hepatitis C”
Refreshments Provided by Midland Medical
and Pride RX Pharmacy
 
 Fortunately, in the past three months, there have been great advances in the treatment of Hepatitis C for both people who have the virus and those who also infected with HIV.  It is my pleasure to present the options that are available now and to answer any questions.

Viral hepatitis has been affected the LGTB community since before the HIV epidemic. The medical community has made great strides in eradicating hepatitis A and B with the advent of vaccinations and anti-viral medications.  Hepatitis C, however, has been an immense challenge for health care providers and their patients due to its tenacity to treatment to a very limited set of options.    I look forward to meeting with you all!

 

Photo
photo of Dr. Patrick Kenney
DR PATRICK KENNEY
Specialist in Infectious Disease: General Infectious Disease, HIV/AIDS Medicine, International Health, Travel & Tropical, STD Medicine, Transplant/Immunocompromised States, Healthcare Associated Infections

954-565-0875  1421 E. Oakland Park Blvd, Suite #101
Oakland Park, FL

Read Full Post »

 

MARCH 19, 2014
 
SPECIAL SPEAKER: DR. PATRICK KENNEY
 
Topic for Wed Group is “New Treatment For
Hepatitis C”
 
Refreshments Provided by Midland Medical
and Pride RX Pharmacy
 
 Fortunately, in the past three months, there have been great advances in the treatment of Hepatitis C for both people who have the virus and those who also infected with HIV.  It is my pleasure to present the options that are available now and to answer any questions.

Viral hepatitis has been affected the LGTB community since before the HIV epidemic. The medical community has made great strides in eradicating hepatitis A and B with the advent of vaccinations and anti-viral medications.  Hepatitis C, however, has been an immense challenge for health care providers and their patients due to its tenacity to treatment to a very limited set of options.    I look forward to meeting with you all!

 

  
Photo
 
photo of Dr. Patrick Kenney
 
DR PATRICK KENNEY
Specialist in Infectious Disease: General Infectious Disease, HIV/AIDS Medicine, International Health, Travel & Tropical, STD Medicine, Transplant/Immunocompromised States, Healthcare Associated Infections

954-565-0875  1421 E. Oakland Park Blvd, Suite #101
Oakland Park, FL

 
 

Read Full Post »

Hep C News

HepCFriends-

We all agree that it’s time to get serious about fighting the growing health care issues surrounding Hepatitis C. That is why I am excited to share the great news that Rep. Mia Jones, who represents Jacksonville in the Florida House of Representatives, has filed legislation to ensure that getting tested and follow-up treatment becomes a regular occurrence among Floridians, especially “Baby Boomers”.

Two weeks ago, I joined Rep. Jones and a number of Florida health care advocates at a press conference in Tallahassee to further the dialogue on why we it’s so critical to pass this legislation.

HepCPic

The most recent Hepatitis C numbers noted below tell the story of why our lawmakers should support Rep. Jones legislation.

4 million U.S. residents are living with HCV.
17,000 new HCV infections occur annually in the United States.
15,000 deaths occur each year-now exceeding those who die of HIV.
300,000 Floridians are living with HCV.

Today, there are a number of effective new treatments available that can prevent serious health conditions associated with Hepatitis C such liver damage, cirrhosis, and even liver cancer.

The AIDS Institute applauds Rep. Jones for her early effort to bring awareness to Hepatitis C and the need to get tested and seek treatment. We know that getting tested can help people learn if they are infected and get them the lifesaving care and treatment they need.

Our work to combat this silent epidemic begins today. Join me in supporting Rep. Jones’ legislation, House Bill 465 and help us pass this important legislation this year.

Please use these links to contact your legislators and ask them to lend their support to HB465 today.

State Senate: http://www.flsenate.gov/Senators/Find

State House: http://www.myfloridahouse.gov/sections/representatives/myrepresentative.aspx

Sincerely,

Michael Ruppal

Executive Director

The AIDS Institute

Read Full Post »

Hepatitis C Cure

Together, two drugs clear the hepatitis C virus without the severe side effects of older treatments, holding out the promise of a cure.

To read full article CLICK HERE

Read Full Post »

I would like to announce and invite you to attend the ABCs of Hep and Health. On Thursday, June 23rd at 7pm (6:30 for refreshments) Infectious Disease Specialist Dr. James T. Dwyer and BioScript pharmacists Diona Libonati and Daniel Elmore will give the community an educational presentation examining Hepatitis A, B, & C, Co-infection with HIV and the latest treatments. See attachment. Please forward this information to your colleagues and clients. I look forward to seeing you all!

Michael Childers

Read Full Post »

Hepatitis C Rapid Test
OraSure Technologies, Inc.
In February of this year, OraSure Technologies received U.S. Food and Drug Administration
(FDA) approval for a rapid hepatitis C test. The approval for the new OraQuick HCV Rapid
Antibody finger-stick test follows about eight months after the FDA approved a similar
blood-draw test for the blood-borne pathogen.
The difference between the tests is how the sample is obtained, said Ron Ticho, OraSure’s
vice president of communications. “This particular procedure now does not require a blood
draw. Instead, it can be done with a simple prick of the finger and a smaller sample of
blood, similar to a diabetes blood test. The approval makes the test more versatile,” he
added, “and will help health care professionals to identify more individuals with this disease.”
The company plans to make it even less invasive, eventually looking to obtain approval for an oral fluid
version of the test, similar to the process used to develop its HIV tests.
For more information, go to: http://www.orasure.com/
——————————————————————————————————————————-

Read Full Post »

From Poz magazine, there is an article in the March issue about Telaprevir, the first protease inhibitor (PI) for treatment of hepatitisC, that’s awaiting FDA approval. Telaprevir has proven effective in people with hard-to-treat hep-C genotype 1. In trials, adding telaprevir to standard hep-C treatment (peglated interferon plus ribavirin) shortened treatment time and cleared the virus.

Read Full Post »

HIV-Positive Men Who Bareback Should Have More Frequent Hep C Testing

Some key points from article:

A new study has found that 75 percent of new hepatitis C virus (HCV) infections in HIV-positive men occurred in those with no history of injection drug use (IDU)

Because of shared transmission routes, up to 30 percent of people with HIV in the United States also have chronic HCV infection. Chronic liver disease is a leading cause of death in people with HIV, and people coinfected with both HIV and HCV are also at a higher risk of death from a number of non-liver-related diseases, including kidney disease.

The majority of HCV cases in the United States are attributable to injection drug use, but there have been reports of HCV transmission in MSM who have no IDU history. Studies of these cases have suggested that HCV risk in these individuals is associated with various sexual practices, including unprotected anal intercourse, the use of sex toys, multiple partners and fisting.

In those studies, barebacking, coinfection with syphilis, and sex that is traumatic to the anus were highly associated with HCV infection in those with no IDU history.

Regular screening for HCV is crucial for two reasons.
1. Many who develop chronic HCV infections do not exhibit symptoms until they are quite ill years later.
2. When people are able to catch their HCV infection early—within a few weeks or months after exposure—HCV treatment is far more likely to work.

Read Full Post »

Human HIV drug trial near

CD4 T-cells are one measurement of the body’s immune system. Another cell that fights infections are called Natural Killer Cells (NK). These are a kind of white blood cell that play a major role in the rejection of tumors and cells infected with viruses.

But they don’t seem to attack cells infected with HIV and that has puzzled scientists for more than two decades. This article explains how HIV produces a protein called Vpu which basically neutralizes the NK cells preventing them from attacking the infected cells.

This new drug, BIT225, targets the Vpu protein of HIV which would then allow the NK cells to do their job. Which means this would be a new class of drugs in the fight against HIV.

“An Australian biomedical research company, Biotron Ltd, already has a drug that specifically targets the Vpu protein of HIV.

The discovery has excited Australian biomedical research company Biotron Ltd which has a drug that specifically targets the Vpu protein of HIV.

The drug has passed through early safety trials, and the company hopes to implement an efficacy trial with HIV-positive patients in the near future.

“This study is really important for Biotron,” said Biotron CEO Dr Michelle Miller.

“We have been working on developing drugs to target the Vpu protein of HIV for several years and, until recently, there has been very little known about exactly how Vpu works, despite good evidence that it is critical to the process of establishing HIV infections in specific cell types.”

From their company web site:

Based on the company info for Biotron, they have an efficacy trial in the works. Looks like there should be a definitive answer in about two years, to how well the treatment might work in humans.

This is a snip from their investor PDF. Looks like their avenue of research is at least promising (not just another ARV). Given the Rush Univ publication, I would think funding will now not be a problem. Because recent studies have shown that if you are adherent to your meds, the chance of resistance is extremely low, investors no longer see new HIV drugs worth the $$$. That’s why this recent news is so important. Otherwise this trial may have come up empty looking for scarce public funding.

• First-in-class new anti-HIV drug
• New mode of action – inhibits budding of virus from infected cells
• Targets HIV in viral reservoirs in vivo
• Reservoirs are last of the holy grail in HIV
• No existing drugs target this source of HIV in the body
• Eradication of reservoirs is essential for “cure” of HIV
• Phase Ib/IIa trial protocols finalised
• 12 – 20 subject trial in HIV+ patients
•Trial designed to demonstrate proof-of-concept i.e. can reduce HIV
loads in HIV-infected reservoir cells in man
• Expected to commence once funding in place

Additional links on related information:

News releases on the drug:

New class of drug in offering

http://www.biospectrumasia.com/content/251110AUS14722.asp

International study supports Biotron’s HIV drug approach

Biotron Presentation to Investors explaining drug’s importance

We will talk about this drug in the second half of the 12-15-2010 Wednesday group meeting.

-Steve

Read Full Post »

Older Posts »